Joint Research Agreement with Xyphos/Astellas on cancer immunotherapy program

January 14th, 2021 | Press Release

We have entered into a joint research agreement with Xyphos, a U.S. subsidiary of Astellas Pharma for the research and development of next-generation cancer immunotherapy using our proprietary nanotechnology.

Back to Press releases

We want to provide you with the most important information and services in the best possible way. In order to do this, we need your consent to use the web analysis tool »Google Analytics« to create and evaluate an anonymous analysis of your visit for statistical purposes. You can change your consent at any time on the data protection page, otherwise it will remain valid for twelve months.